Wendy Barnes compensation by year
GoodRx Summary Compensation Table · the one fiscal year held| Component | FY2025 |
|---|---|
| Salary | $825,000 |
| Bonus | $2,550,000 |
| Stock awards | $10,921,182 |
| Option awards | $9,000,000 |
| Non-equity incentive | $0 |
| Pension and deferred compensation | $0 |
| All other | $71,301 |
| Total | $23,367,483 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: GoodRx Holdings, Inc. DEF 14A filed April 29, 2026, accession 0001809519-26-000091, and prior-year filings.
How this page was built: the GoodRx Holdings, Inc. filed document, accession 0001809519-26-000091. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 1,842,374 | $4,992,834 | — |
| RSU | 409,416 | $1,109,517 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in GoodRx Holdings, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
18 Form 4 lines since the FY2025 proxy (filed April 29, 2026)current to 2026-11-07 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-10-15 | Tax withholding | — | 50,021 | $3.38 | 806,785 |
| 2026-10-15 | Exercise or conversion | — | 51,177 | — | 857,962 |
| 2026-10-15 | Tax withholding | — | 48,203 | $3.38 | 898,490 |
| 2026-10-15 | Exercise or conversion derivative | — | 115,149 | $0.00 | 1,036,335 |
| 2026-10-15 | Exercise or conversion derivative | — | 110,963 | $0.00 | 998,668 |
| 2026-10-15 | Tax withholding | — | 22,232 | $3.38 | 835,730 |
| 2026-10-15 | Exercise or conversion | — | 110,963 | — | 946,693 |
| 2026-10-15 | Exercise or conversion | — | 115,149 | — | 856,806 |
The 8 most recent of 18 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments GoodRx discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Change in control and involuntary termination | $1,237,500 | $3,501,917 | $66,441 | $4,805,858 |
| Change in control and resignation for good reason | $1,237,500 | $3,501,917 | $66,441 | $4,805,858 |
| Involuntary termination without cause | $825,000 | $1,109,517 | $44,294 | $1,978,811 |
| Disability | $0 | $0 | $0 | $0 |
| Death | $0 | $0 | $0 | $0 |
| Change in control, no termination | $0 | $0 | $0 | $0 |
| Resignation for good reason, no change in control | $825,000 | $1,109,517 | $44,294 | $1,978,811 |
Per the Potential Payments Upon Termination or Change in Control table in GoodRx Holdings, Inc.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
GoodRx’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Wendy Barnes · this page | Chief Executive Officer & President | $23,367,483 |
| Christopher McGinnis | Chief Financial Officer & Treasurer | $8,698,916 |
| Romin Nabiey | Chief Accounting Officer and Former Interim Chief Financial Officer | $1,256,668 |
| Trevor Bezdek | Co-Chairman of the Board | $971,608 |
| Scott Wagner | Former Interim Chief Executive Officer | $856,780 |
| Karsten Voermann | Former Chief Financial Officer | $280,256 |
Board service
GoodRx board · FY2025How this board is paid
Company policy: GoodRx pays directors a $30,000 cash retainer and $230,000 in RSUs. As stated in GoodRx's FY2025 proxy.
The full GoodRx compensation record
free company briefThis page is one person within GoodRx's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the GoodRx proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order GoodRx's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are GoodRx's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.